Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03696277 · ClinicalTrials.gov registry record · Phase 2
SAbR For Oligo-Progressive Renal Cell Cancer.
A Phase 2 study of Oligoprogressive Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT03696277: Completed Phase 2 study of Oligoprogressive Renal Cell Carcinoma, sponsored by University of Texas Southwestern Medical Center.
NCT03696277 is a Phase 2 study of Oligoprogressive Renal Cell Carcinoma that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 21 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03696277, a Phase 2 study of Oligoprogressive Renal Cell Carcinoma, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy. Local therapy to the sites of progression may allow patients to continue on the same systemic therapy that is otherwise effective and being tolerated well. Hypothesis: Stereotactic ablative radiation (SAbR) can delay the change of systemic therapy with oligoprogressive renal cell cancer (RCC) and improve progression free survival (PFS). Primary Objectives: • To evaluate the benefit of SAbR for oligo-progressive mRCC (Metastatic Renal Cell Cancer). Secondary Objectives: • To measure the toxicity, safety and tolerance of concurrent systemic therapy and SAbR for mRCC patients and its impact on quality of life.
Primary Outcome
SAbR for oligo-progression will be measured to delay the change of systemic therapy.
Conditions Studied
Interventions
- RADIATION Stereotactic ablative body radiation (SABR)
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
What the finished NCT03696277 record still lists
NCT03696277 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Oligoprogressive Renal Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Stereotactic ablative body radiation (SABR) is the first listed.
NCT03696277 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT03696277 about?
NCT03696277 is a clinical study titled "SAbR For Oligo-Progressive Renal Cell Cancer.". Metastatic kidney cancer patients on systemic therapy often develop resistance to limited sites that leads to changing of the systemic therapy. Local therapy to the sites of progression may allow patients to continue on the same systemic therapy that is otherwise effective and being tolerated well. ...
What is the current status of trial NCT03696277?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-10-01. Estimated completion is 2024-01-23.
What conditions does trial NCT03696277 study?
This clinical trial studies the following conditions: Oligoprogressive Renal Cell Carcinoma.
What interventions are being tested in trial NCT03696277?
The interventions under investigation include: Stereotactic ablative body radiation (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03696277?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03696277 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03696277's enrollment target sits among peer trials
21 1794th of 2000 higher than 196 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI